Heart plaque Dx co gets $17m
This article was originally published in Clinica
Executive Summary
Burlington, Massachusetts-based InfraReDx has raised $17m in new capital to initiate commercialisation of its near-infrared, catheter-based diagnostics system for detecting arterial plaque. The financing round, the company's third to date, was led by Sanderling Ventures and included the participation of new and existing individual investors, according to VentureWire. InfraReDx is expecting its technology to help prevent a second heart attack in patients who have already suffered a coronary event. The company is planning a limited roll-out of the system pending FDA approval, which is expected this quarter.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.